Cornelia B Landersdorfer1,2,3, Robert L Findling4,5, Jean A Frazier6, Vivian Kafantaris7, Carl M J Kirkpatrick8. 1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University (Parkville campus), 381 Royal Parade, Parkville, VIC, 3052, Australia. Cornelia.Landersdorfer@monash.edu. 2. Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia. Cornelia.Landersdorfer@monash.edu. 3. Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, NY, USA. Cornelia.Landersdorfer@monash.edu. 4. Child and Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD, USA. 5. Psychiatry, Kennedy Krieger Institute, Baltimore, MD, USA. 6. Child and Adolescent Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA. 7. The Zucker Hillside Hospital, Glen Oaks, NY, USA. 8. Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University, Melbourne, VIC, Australia.
Abstract
BACKGROUND:Lithium is a well-established treatment for bipolar I disorder in adults. However, there is a paucity of information on its pharmacokinetics/pharmacodynamics in children and adolescents. We aimed to develop the first lithium dosage regimens based on population pharmacokinetics/pharmacodynamics for paediatric patients. METHODS:Lithium concentrations, Young Mania Rating Scale (YMRS) and Clinical Global Impressions-Improvement (CGI-I) scores over 24 weeks were available from 61 paediatric patients with bipolar I disorder. The population pharmacokinetics/pharmacodynamics were co-modelled. Concentrations and clinical effects following several dosage regimens were predicted by Monte Carlo simulations. RESULTS: The pharmacokinetics were well characterised by a two compartment model with linear elimination. Including the effect of total body weight (TBW) or lean body weight (LBW) on clearance and volume of distribution decreased the unexplained inter-individual variability by up to 12 %. The population mean (inter-individual variability) clearance was 1.64 L/h/53 kg LBW0.75 (19 %) and central volume of distribution 23.6 L/53 kg LBW (6.8 %). The average lithium concentration over a dosing interval required for a 50 % reduction in YMRS was 0.711 mEq/L (59 %). A maintenance dose of 25 mg/kg TBW/day lithium carbonate in two daily doses was predicted to achieve a ≥50 % reduction in YMRS in 74 % of patients, while ~8 % of patients would be expected to have trough concentrations above the nominal safety threshold of 1.4 mEq/L. Therefore, therapeutic drug monitoring will still be required even with these dosing strategies. CONCLUSIONS: When accounting for body size, the pharmacokinetic parameters in paediatric patients were within the range of estimates from adults. Pharmacokinetic/pharmacodynamic modelling supported development of practical scientifically-based dosage regimens for paediatric patients.
RCT Entities:
BACKGROUND:Lithium is a well-established treatment for bipolar I disorder in adults. However, there is a paucity of information on its pharmacokinetics/pharmacodynamics in children and adolescents. We aimed to develop the first lithium dosage regimens based on population pharmacokinetics/pharmacodynamics for paediatric patients. METHODS:Lithium concentrations, Young Mania Rating Scale (YMRS) and Clinical Global Impressions-Improvement (CGI-I) scores over 24 weeks were available from 61 paediatric patients with bipolar I disorder. The population pharmacokinetics/pharmacodynamics were co-modelled. Concentrations and clinical effects following several dosage regimens were predicted by Monte Carlo simulations. RESULTS: The pharmacokinetics were well characterised by a two compartment model with linear elimination. Including the effect of total body weight (TBW) or lean body weight (LBW) on clearance and volume of distribution decreased the unexplained inter-individual variability by up to 12 %. The population mean (inter-individual variability) clearance was 1.64 L/h/53 kg LBW0.75 (19 %) and central volume of distribution 23.6 L/53 kg LBW (6.8 %). The average lithium concentration over a dosing interval required for a 50 % reduction in YMRS was 0.711 mEq/L (59 %). A maintenance dose of 25 mg/kg TBW/day lithium carbonate in two daily doses was predicted to achieve a ≥50 % reduction in YMRS in 74 % of patients, while ~8 % of patients would be expected to have trough concentrations above the nominal safety threshold of 1.4 mEq/L. Therefore, therapeutic drug monitoring will still be required even with these dosing strategies. CONCLUSIONS: When accounting for body size, the pharmacokinetic parameters in paediatric patients were within the range of estimates from adults. Pharmacokinetic/pharmacodynamic modelling supported development of practical scientifically-based dosage regimens for paediatric patients.
Authors: Robert L Findling; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Brieana M Rowles; Traci E Clemons; Perdita Taylor-Zapata Journal: J Child Adolesc Psychopharmacol Date: 2011-06 Impact factor: 2.576
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Samira Menegas; Gustavo C Dal-Pont; José H Cararo; Roger B Varela; Jorge M Aguiar-Geraldo; Taise Possamai-Della; Monica L Andersen; João Quevedo; Samira S Valvassori Journal: Metab Brain Dis Date: 2019-12-15 Impact factor: 3.584
Authors: Rachel G Greenberg; Cornelia B Landersdorfer; Nazario Rivera-Chaparro; Melissa Harward; Thomas Conrad; Aya Nakamura; Carl M Kirkpatrick; Kenan Gu; Varduhi Ghazaryhan; Blaire Osborn; Emmanuel B Walter Journal: Paediatr Drugs Date: 2022-03-14 Impact factor: 3.022